

Wen-Juei Jeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4170152/publications.pdf>

Version: 2024-02-01

241
papers

8,616
citations

61687

45
h-index

68831

81
g-index

248
all docs

248
docs citations

248
times ranked

11089
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
2	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2022, 226, 441-452.	1.9	18
3	Plasma and ascites pharmacokinetics of meropenem in patients with decompensated cirrhosis and spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2022, 76, 230-233.	1.8	2
4	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	2.0	15
5	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. <i>Hepatology Communications</i> , 2022, 6, 621-632.	2.0	2
6	Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1890-1891.	2.4	1
7	Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. <i>Clinical Research in Cardiology</i> , 2022, 111, 233-236.	1.5	5
8	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , 2022, 71, 2300-2312.	6.1	37
9	Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection. <i>JHEP Reports</i> , 2022, 4, 100410.	2.6	6
10	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. <i>European Journal of Immunology</i> , 2022, 52, 472-483.	1.6	8
11	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 213-219.	0.8	10
12	HCC and HBV reactivation—A preventable condition not to be missed. <i>Hepatology</i> , 2022, 75, 1075-1077.	3.6	1
13	Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 558-567.	1.9	5
14	Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. <i>Liver International</i> , 2022, 42, 551-560.	1.9	20
15	Innate-like bystander-activated CD38+HLA-DR+CD8+T cells play a pathogenic role in patients with chronic hepatitis C. <i>Hepatology</i> , 2022, 76, 803-818.	3.6	11
16	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
17	Reverse Inflammaging: Biological age is accelerated in chronic HCV patients and decelerates after HCV cure. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
18	Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy. <i>Liver International</i> , 2022, 42, 945-946.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis. <i>Scientific Reports</i> , 2022, 12, 3285.	1.6	0
20	The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. <i>Virology Journal</i> , 2022, 19, 59.	1.4	0
21	Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 665.	1.3	4
22	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 863039.	2.2	10
23	Letter: s <sc>PD</sc> as a predictor for <sc>HB</sc> s <sc>A</sc> g seroclearance shed light on inactive carriers with chronic hepatitis B. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1057-1058.	1.9	0
24	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	1.0	14
25	Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. <i>Cancer Medicine</i> , 2022, 11, 3786-3795.	1.3	5
26	Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2022, 57, 423-432.	2.3	2
27	OMIP-084: 28-color full spectrum flow cytometry panel for the comprehensive analysis of human T cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 856-861.	1.1	7
28	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. <i>Advances in Therapy</i> , 2022, 39, 3146-3158.	1.3	6
29	Unsolved issues in treatment for grey zone chronic hepatitis B patients. <i>Hepatology International</i> , 2022, , .	1.9	0
30	Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 529-539.	1.9	5
31	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
32	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
33	The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 475-483.	1.0	4
34	A transient early HBV-DNA increase during PEG-IFN± therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBeAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	1.0	5
35	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFN± based antiviral treatment of hepatitis delta: Results from the HIDIT study. <i>Liver International</i> , 2021, 41, 295-299.	1.9	18
36	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Reply to letter to the editor: The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 785-786.	0.8	0
38	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. <i>Hepatology Communications</i> , 2021, 5, 97-111.	2.0	16
39	Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 99-117.	2.3	15
40	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	5.8	71
41	COVID-19 immune signatures reveal stable antiviral T _H cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
42	Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 486-496.	1.6	5
43	Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4492-4500.	1.1	6
44	Utility of quantitative ultrasound in community screening for hepatic steatosis. <i>Ultrasonics</i> , 2021, 111, 106329.	2.1	8
45	The unsolved issues in oral antiviral therapy in HBeAg positive chronic hepatitis B patients. <i>Advances in Digestive Medicine</i> , 2021, 8, 5-7.	0.1	0
46	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , 2021, 41, 1815-1823.	1.9	4
47	EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 74, 944-951.	1.8	168
48	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. <i>Cancers</i> , 2021, 13, 1729.	1.7	14
49	The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 527-528.	1.9	0
50	Experimental Drugs for the Treatment of Hepatitis D. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 461-468.	1.5	16
51	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C Registry. <i>Liver International</i> , 2021, 41, 1518-1522.	1.9	9
52	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2021, 41, 2046-2058.	1.9	3
53	Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. <i>Frontiers in Public Health</i> , 2021, 9, 667253.	1.3	3
54	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab325.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting" results from the German Hepatitis C Registry (DHC Registry). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1206-1218.	1.0	13
56	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021, 74, 72-82.	3.6	19
57	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
58	Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. <i>Seminars in Liver Disease</i> , 2021, 41, 349-357.	1.8	15
59	Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , 2021, 27, 887-899.	1.3	4
60	Disputing issues in the paradigm change to finite antiviral therapy in HBeAg-negative patients. <i>Journal of Hepatology</i> , 2021, 75, 1498-1499.	1.8	2
61	Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 910-911.	4.6	0
62	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 833-851.	1.9	43
63	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , 2021, 75, 229-231.	1.8	3
64	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , 2021, 21, 296.	0.8	2
65	Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CART T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 721738.	2.2	5
66	Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?. <i>Journal of Hepatology</i> , 2021, 75, 487-489.	1.8	10
67	Impact of the COVID-19 pandemic on patients with liver cirrhosis"the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 954-960.	0.2	2
68	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , 2021, 142, 104932.	1.6	19
69	Should Treatment Indications for Chronic Hepatitis B Be Expanded?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2006-2014.	2.4	45
70	Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 205-212.	1.3	8
71	Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 415-423.	0.8	1
72	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 223-229.	0.8	3

#	ARTICLE	IF	CITATIONS
73	MELD score is the better predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by trans-arterial embolization. <i>American Journal of Cancer Research</i> , 2021, 11, 3726-3734.	1.4	1
74	Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4956-4965.	1.4	2
75	Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 418.	7.1	54
76	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. <i>Liver International</i> , 2020, 40, 539-548.	1.9	24
77	The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 635-643.	0.8	7
78	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
79	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , 2020, 40, 324-332.	1.9	13
80	Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1192-1199.	0.8	9
81	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 194-195.	1.9	8
82	Understanding More About Hepatitis Flare in Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 266-267.	2.4	3
83	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
84	Global timing of hepatitis C virus elimination in high-income countries. <i>Liver International</i> , 2020, 40, 522-529.	1.9	147
85	Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 23.	1.7	7
86	Editorial: which factors influence HBsAg levels in HBV-infected patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 547-548.	1.9	3
87	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	2.7	109
88	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , 2020, 72, 1378-1393.	3.6	29
89	Reply letter to "The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients: Bystander rather than offender". <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1564-1565.	0.8	0
90	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	1.0	47

#	ARTICLE	IF	CITATIONS
91	UEG framework for the development of high-quality clinical guidelines. United European Gastroenterology Journal, 2020, 8, 851-864.	1.6	9
92	Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. Frontiers in Public Health, 2020, 8, 424.	1.3	30
93	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Reports, 2020, 2, 100169.	2.6	120
94	Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation. International Journal of Hyperthermia, 2020, 37, 1008-1015.	1.1	3
95	Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver International, 2020, 40, 1507-1507.	1.9	0
96	Impact of hepatic steatosis on treatment response in nucleos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterology, 2020, 20, 146.	0.8	14
97	Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. United European Gastroenterology Journal, 2020, 8, 567-576.	1.6	13
98	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	1.8	39
99	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. Cells, 2020, 9, 1471.	1.8	6
100	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. PLoS ONE, 2020, 15, e0235199.	1.1	7
101	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. Journal of Clinical Virology, 2020, 129, 104525.	1.6	2
102	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Advances in Digestive Medicine, 2020, 7, 83-92.	0.1	2
103	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. Journal of Hepatology, 2020, 72, 1112-1121.	1.8	62
104	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infectious Diseases, 2020, 7, ofaa040.	0.4	17
105	Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clinical Gastroenterology and Hepatology, 2020, 18, 2803-2812.e2.	2.4	28
106	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports, 2020, 2, 100113.	2.6	378
107	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE, 2020, 15, e0230893.	1.1	2
108	Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (United States), 2020, 99, e21898.	0.4	4

#	ARTICLE	IF	CITATIONS
109	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 841-846.	0.2	4
110	Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 696-706.	1.9	47
111	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1033-1041.	0.6	13
112	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0220666.	1.1	11
113	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 889-899.	1.8	52
114	Gallbladder Polyps Are Associated with Proximal Colon Polyps. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-10.	0.7	7
115	High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. <i>Cancers</i> , 2019, 11, 1549.	1.7	12
116	Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. <i>Current Hepatology Reports</i> , 2019, 18, 512-521.	0.4	2
117	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2076.	2.2	11
118	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 14118.	1.6	14
119	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 673-684.	1.8	25
120	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. <i>Cells</i> , 2019, 8, 610.	1.8	5
121	Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 930-930.	1.0	2
122	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019, 71, 301-312.	1.8	62
123	Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBsAg-negative patients. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1019-1026.	1.0	17
124	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019, 156, 1820-1833.	0.6	44
125	Letter to the Editor: Deliberations More Than a Cutoff Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation. <i>Hepatology</i> , 2019, 70, 1488-1489.	3.6	1
126	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1239-1246.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	4.6	128
128	IDDF2019-ABS-0212â€œ...Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis. , 2019, , .		0
129	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	4.2	38
130	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	1.8	90
131	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <i>Gastroenterology</i> , 2019, 156, 400-417.	0.6	35
132	Clinical Practice Guidelines of the European Association for the study of the Liver â€œ Advancing methodology but preserving practicability. <i>Journal of Hepatology</i> , 2019, 70, 5-7.	1.8	31
133	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018, 93, 150-153.	1.3	43
134	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2018, 217, 1656-1666.	1.9	57
135	Doseâ€œdependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. <i>Liver International</i> , 2018, 38, 1602-1613.	1.9	33
136	No cure for hepatitis B and D without targeting integrated viral DNA?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 195-196.	8.2	15
137	Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 961-971.	1.1	3
138	Systemic inflammation and immune cell phenotypes are associated with neuroâ€œpsychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , 2018, 38, 2317-2328.	1.9	9
139	Hepatitis E virus <sc>ORF</sc> 1 induces proliferative and functional Tâ€œcell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018, 38, 266-277.	1.9	18
140	Clinical and virological heterogeneity of hepatitis delta in different regions worldâ€œwide: The Hepatitis Delta International Network (<sc>HDIN</sc>). <i>Liver International</i> , 2018, 38, 842-850.	1.9	72
141	Realâ€œworld effect of ribavirin on quality of life in <sc>HCV</sc> â€œinfected patients receiving interferonâ€œfree treatment. <i>Liver International</i> , 2018, 38, 834-841.	1.9	9
142	Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigenâ€œnegative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 425-434.	3.6	219
143	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , 2018, 68, 851-853.	1.8	5
144	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 26, 466-475.	1.0	6

#	ARTICLE	IF	CITATIONS
145	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018, 6, 1188-1198.	1.6	23
146	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e189.	1.3	23
147	New viral biomarkers for Hepatitis B: Are we able to change practice?. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1226-1235.	1.0	21
148	Reply to Liaw. <i>Journal of Infectious Diseases</i> , 2018, 218, 1853-1854.	1.9	0
149	Human γ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 510.	2.2	31
150	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 584-593.	1.8	95
151	HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients. <i>Gastroenterology</i> , 2018, 154, 2280-2281.	0.6	33
152	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , 2018, 9, 2275.	5.8	75
153	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 1480-1484.	1.9	38
154	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.4	4
155	Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. <i>Liver International</i> , 2017, 37, 67-72.	1.9	6
156	What is new on HBsAg and other diagnostic markers in HBV infection?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 281-289.	1.0	28
157	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	1.6	16
158	Serum HBsAg kinetics in clinical prediction. <i>Journal of Hepatology</i> , 2017, 67, 192-193.	1.8	1
159	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 848-856.	0.2	16
160	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 609-618.	1.4	10
161	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. <i>Journal of Hepatology</i> , 2017, 67, 918-924.	1.8	230
162	Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 1905-1910.	0.8	26

#	ARTICLE	IF	CITATIONS
163	Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. <i>Scientific Reports</i> , 2017, 7, 15280.	1.6	16
164	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017, 67, 680-686.	1.8	37
165	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 215-222.	4.6	109
166	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017, 215, 139-149.	1.9	32
167	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017, 65, 414-425.	3.6	88
168	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	1.8	267
169	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. <i>Liver International</i> , 2017, 37, 205-211.	1.9	37
170	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , 2017, 8, 525.	2.2	25
171	Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1210.	2.2	50
172	RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2017, 17, 742.	1.1	27
173	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw572.	1.3	1
174	Article Commentary: Importance of IP-10 in Hepatitis B. <i>Antiviral Therapy</i> , 2016, 21, 93-96.	0.6	13
175	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	2.4	61
176	Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1813-1820.e1.	2.4	69
177	Nonreversible MAIT cell dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , 2016, 46, 2204-2210.	1.6	142
178	Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. <i>Biomedical Journal</i> , 2016, 39, 400-406.	1.4	9
179	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016, 65, 473-482.	1.8	64
180	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016, 214, 1492-1497.	1.9	114

#	ARTICLE	IF	CITATIONS
181	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , 2016, 65, 1733-1743.	6.1	145
182	Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2016, 214, 1965-1974.	1.9	127
183	Hepatitis C: individualised medicine versus one pill fits all. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 86-87.	3.7	5
184	The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , 2016, 36, 473-476.	1.9	3
185	Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1346-1353.	0.7	41
186	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	2.4	51
187	Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 329-336.	0.6	34
188	Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , 2016, 16, 41-48.	2.6	22
189	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	2.9	23
190	±-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1601-1608.	1.3	18
191	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567.	2.9	89
192	Factors predicting organ-specific distant metastasis in patients with completely resected lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 58261-58273.	0.8	15
193	Comprehensive phenotyping of regulatory T cells after liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 381-395.	1.3	7
194	Prognostic Factors of Survival after Recurrence in Patients with Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1328-1336.	0.5	35
195	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , 2015, 35, 2275-2284.	1.9	0
196	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , 2015, 6, 270.	2.2	27
197	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0128069.	1.1	5
198	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015, 10, e0145622.	1.1	2

#	ARTICLE	IF	CITATIONS
199	When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 260-262.	1.0	9
200	Altered effector functions of NK cells in chronic hepatitis C are associated with <i>IFNL3</i> polymorphism. <i>Journal of Leukocyte Biology</i> , 2015, 98, 283-294.	1.5	11
201	Insufficient Ablative Margin Determined by Early Computed Tomography May Predict the Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Liver Cancer</i> , 2015, 4, 26-38.	4.2	77
202	Heterogeneity of hepatocellular carcinoma contributes to cancer progression. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 337-347.	2.0	74
203	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , 2015, 35, 1845-1852.	1.9	25
204	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8 ⁺ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , 2015, 89, 8304-8317.	1.5	32
205	Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2015, 210, 554-560.	0.9	17
206	Differences in Liver Fibrosis Between Patients With Chronic Hepatitis B and C. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 813-821.	0.8	23
207	Clinical Events After Cessation of Lamivudine Therapy in Patients Recovered From Hepatitis B Flare With Hepatic Decompensation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 979-986.	2.4	33
208	<i>IL28B</i> polymorphism and early anemia predict the rapid null response in genotype 1 chronic hepatitis C with dual therapy. <i>Advances in Digestive Medicine</i> , 2015, 2, 128-134.	0.1	0
209	Effects of HDV infection and pegylated interferon treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , 2015, 64, 469-482.	6.1	51
210	Blockade of TNF signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. <i>Oncoimmunology</i> , 2015, 4, e1040215.	2.1	40
211	Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis. <i>Journal of Virology</i> , 2015, 89, 10786-10801.	1.5	23
212	New kids on the block—step by step to an ideal HCV therapy. <i>Lancet, The</i> , 2015, 385, 1050-1052.	6.3	10
213	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 31-40.	1.8	50
214	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	1.1	15
215	Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 2357-2364.	0.8	228
216	HBsAg seroclearance with NUCs: rare but important. <i>Gut</i> , 2014, 63, 1208-1209.	6.1	26

#	ARTICLE	IF	CITATIONS
217	Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment. <i>Digestive Diseases</i> , 2014, 32, 747-754.	0.8	18
218	Finite entecavir therapy is a feasible alternative to indefinite therapy. <i>Hepatology</i> , 2014, 60, 1796-1797.	3.6	0
219	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e94512.	1.1	17
220	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	1.1	50
221	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. <i>Current Hepatitis Reports</i> , 2013, 12, 261-268.	0.3	0
222	Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Hepatology</i> , 2013, 58, 1888-1896.	3.6	196
223	High Expression of Patched Homolog-1 Messenger RNA and Glioma-Associated Oncogene-1 Messenger RNA of Sonic Hedgehog Signaling Pathway Indicates a Risk of Postresection Recurrence of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 464-473.	0.7	32
224	Clonal Exhaustion as a Mechanism to Protect Against Severe Immunopathology and Death from an Overwhelming CD8 T Cell Response. <i>Frontiers in Immunology</i> , 2013, 4, 475.	2.2	83
225	Patients younger than forty years old with hepatitis C virus genotype 1 chronic infection had treatment responses similar to genotype 2 infection and not related to interleukin 28B polymorphism. <i>Annals of Hepatology</i> , 2013, 12, 62-69.	0.6	5
226	Natural killer cells act as rheostats modulating antiviral T cells. <i>Nature</i> , 2012, 481, 394-398.	13.7	542
227	Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer. <i>Chest</i> , 2012, 142, 141-150.	0.4	36
228	Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 297-302.	2.4	68
229	None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis. <i>PLoS ONE</i> , 2012, 7, e48217.	1.1	3
230	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
231	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	1.9	333
232	Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 541-545.	2.4	54
233	Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. <i>International Journal of Hematology</i> , 2008, 87, 542-544.	0.7	2
234	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-316.	0.6	22

#	ARTICLE	IF	CITATIONS
235	Present and future therapy for hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 781-793.	2.0	11
236	Reply:. <i>Hepatology</i> , 2006, 44, 511-512.	3.6	2
237	Future trends in hepatitis C therapy. <i>Future Virology</i> , 2006, 1, 99-107.	0.9	3
238	New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2005, 4, 144-50.	0.6	0
239	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 37, 843-847.	1.8	29
240	Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G164-G172.	1.6	33
241	Morphological and molecular characterization of human gastric mucous cells in long-term primary culture. <i>Pflügers Archiv European Journal of Physiology</i> , 1998, 436, 871-881.	1.3	10